Clinical Impact of CTLA-4 Single-Nucleotide Polymorphism in DLBCL Patients Treated with CAR-T Cell Therapy
Open Access
- 29 July 2025
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 32 (8) , 425
Abstract
FMC63-CAR T cell therapy targeting CD19 protein on malignant B-cells is effective in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), with complete response rates of 43–54%. Common germline variants of the immune-checkpoint regulator CTLA-4 may elicit different responses to CAR-T cell therapy. The CTLA4 gene single-nucleotide polymorphism rs231775 coding threonine or alanine at amino acid position 17 of the CTLA-4 protein was prevalent in 55% of the studied DLBCL patients. In a retrospective comparative analysis of clinical outcome, there were significant differences in CTLA4 A17hom vs. T17Ahet and T17hom carriers with four-year progression-free survival at 77%, 59%, and 30% (p = 0.019), four-year overall survival was 79%, 41%, and 33% (p = 0.049), the relapse rates were 20%, 37%, and 56% (p = 0.025), and the death rates 20%, 54%, and 52% (p = 0.049). Conclusions: CTLA4 rs231775 polymorphism may impact the treatment outcome in FMC63-anti-CD19 CAR-T cell therapy, with an association of the CTLA4 minor allele A17 to favorable treatment outcome.Keywords
This publication has 31 references indexed in Scilit:
- LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunityCell, 2024
- Impact of the cytotoxic T-lymphocyte associated antigen-4 rs231775 A/G polymorphism on cancer riskHeliyon, 2023
- Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cellsImmunity, 2023
- Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19Cancer Immunology, Immunotherapy, 2022
- Engineered T Cells: CAR T Cell Therapy and BeyondCurrent Oncology Reports, 2022
- Driving the CAR to the Bone Marrow Transplant ProgramCurrent Hematologic Malignancy Reports, 2019
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2019
- Microenvironmental regulation of tumor progression and metastasisNature Medicine, 2013
- Cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) gene polymorphism and susceptibility to non‐Hodgkin's lymphomaAmerican Journal of Hematology, 2004
- A polymorphism in the human cytotoxic T-lymphocyte antigen 4 ( CTLA4 ) gene (exon 1 +49) alters T-cell activationImmunogenetics, 2002